Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo
Official title: This is a Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive Seamless Design, Phase II/III Study Evaluating the Efficacy and Safety of FXS5626 in Participants With Non-segmental Vitiligo
Status: Opening soon
Description:
This is a multicenter, randomized, double-blind, placebo-controlled, adaptive seamless design, Phase II/III study evaluating the efficacy and safety of FXS5626 in participants with non-segmental vitiligo.
Phases: Phase 2, Phase 3.
What is being studied: drugs — Intervention1: FXS5626 Tablets, Intervention2: FXS5626 Tablets, Intervention3: FXS5626 Tablets, Intervention4: FXS5626 Tablets, Intervention5: FXS5626 Placebo Tablets, Intervention6: FXS5626 Placebo Tablets.
Who can take part: ages 12 Years to 75 Years, 480 participants planned.
Enrollment status: Opening soon. The study started 30 October 2026 and is expected to finish 08 December 2027.
Contact: Wenyu Wu.
Source: ClinicalTrials.gov, NCT07840820 (https://clinicaltrials.gov/study/NCT07840820).
Start date: October 30, 2026
Completion date: December 08, 2027
Organizer: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Contact: Wenyu Wu
Tel.: +86 021-52887783
Email: wwylcsy@163.com
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Is there a link between vitiligo and depression?
Depression and anxiety are often linked with vitiligo, significantly impacting a person’s quality of life. The connection stems from the shared origin of the skin and brain duri...
- Can Ginkgo Biloba help with vitiligo?
Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...
- What are the best predictors for therapy response in vitiligo?
A fair question. Also a slightly annoying one, because dermatology loves nuance and patients usually want something more like a weather forecast. Still, a few factors do show up...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.